Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927422" target="_blank" >RIV/00064173:_____/24:43927422 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00136679 RIV/00216208:11110/24:10482327 RIV/00216208:11120/24:43927422 RIV/61989592:15110/24:73626324 and 5 more
Result on the web
<a href="https://doi.org/10.1111/bjh.19670" target="_blank" >https://doi.org/10.1111/bjh.19670</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.19670" target="_blank" >10.1111/bjh.19670</a>
Alternative languages
Result language
angličtina
Original language name
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
Original language description
Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
1365-2141
Volume of the periodical
205
Issue of the periodical within the volume
5
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
1746-1750
UT code for WoS article
001274444700001
EID of the result in the Scopus database
2-s2.0-85199393049